Efficacy and safety of docetaxel for advanced non-small-cell lung cancer: a meta-analysis of Phase III randomized controlled trials

References

• TorreLABrayFSiegelRLFerlayJLortet-TieulentJJemalAGlobal cancer statistics, 2012CA Cancer J Clin2015658710825651787
   PubMed Web of Science ®Google Scholar
• ZhengRSZengHMZhangSWLung cancer incidence and mortality in China, 2010Thorac Cancer20145330336
   PubMed Web of Science ®Google Scholar
• SunYWuYLZhouCCSecond-line pemetrexed versus docetaxel in Chinese patients with locally advanced or metastatic non-small cell lung cancer: a randomized, open-label studyLung Cancer20137914315023182660
   PubMed Web of Science ®Google Scholar
• GovindanRPageNMorgenszternDChanging epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results databaseJ Clin Oncol2006244539454417008692
   PubMed Web of Science ®Google Scholar
• DiBSWeiKPTianJHEffectiveness and safety of pemetrexed versus docetaxel as a treatment for advanced non-small cell lung cancer: a systematic review and meta-analysisAsian Pac J Cancer Prev2014153419342424870732
   PubMedGoogle Scholar
• MolinaJRYangPCassiviSDSchildSEAdjeiAANon-small cell lung cancer: epidemiology, risk factors, treatment, and survivorshipMayo Clin Proc20088358459418452692
   PubMed Web of Science ®Google Scholar
• PetersSAdjeiAAGridelliCReckMKerrKFelipEESMO Guidelines Working GroupMetastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnn Oncol201223Suppl 7vii56vii6422997455
   PubMed Web of Science ®Google Scholar
• SchillerJHHarringtonDBelaniCPEastern Cooperative Oncology GroupComparison of four chemotherapy regimens for advanced non-small-cell lung cancerN Engl J Med2002346929811784875
   PubMed Web of Science ®Google Scholar
• KimHJKimTGLeeHJA phase II study of combination chemotherapy with docetaxel and carboplatin for elderly patients with advanced non-small cell lung cancerLung Cancer20106824825219647333
   PubMed Web of Science ®Google Scholar
• GandaraDRVokesEGreenMActivity of docetaxel in platinum-treated non-small-cell lung cancer: results of a phase II multicenter trialJ Clin Oncol20001813113510623703
   PubMed Web of Science ®Google Scholar
• AdjeiAAPharmacology and mechanism of action of pemetrexedClinical Lung Cancer200455155
   PubMedGoogle Scholar
• PujolJLPaulSChouakiNSurvival without common toxicity criteria grade 3/4 toxicity for pemetrexed compared with docetaxel in previously treated patients with advanced non-small cell lung cancer (NSCLC): a risk-benefit analysisJ Thorac Oncol2007239740117473654
   PubMed Web of Science ®Google Scholar
• BarlettaGGenovaCRijavecEOral vinorelbine in the treatment of non-small-cell lung cancerExpert Opin Pharmacother2014151585159924972635
   PubMed Web of Science ®Google Scholar
• ChangAChemotherapy, chemoresistance and the changing treatment landscape for NSCLCLung Cancer20117131020951465
   PubMed Web of Science ®Google Scholar
• CuiDHPenetrated and docetaxel respectively combined with cisplatin in the treatment of non-small cell lung cancerChinese Journal of Clinical Oncology and Rehabilitation201421820822 Chinese
   Google Scholar
• BaoZChenDLiBResearch on the therapeutic effect and adverse reactions of combination chemotherapy with NVB and TXT on non-small cell lung cancerChinese Journal of Clinical Pharmacology and Therapeutics201419916920 Chinese
   Google Scholar
• JadadARMooreRACarrollDAssessing the quality of reports of randomized clinical trials: is blinding necessary?Control Clin Trials1996171128721797
   PubMedGoogle Scholar
• MoherDPhamBJonesADoes quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?Lancet19983526096139746022
   PubMed Web of Science ®Google Scholar
• HigginsJPThompsonSGDeeksJJAltmanDGMeasuring inconsistency in meta-analysesBMJ200332755756012958120
   PubMed Web of Science ®Google Scholar
• Rodrigues-PereiraJKimJHMagallanesMA randomized phase 3 trial comparing pemetrexed/carboplatin and docetaxel/carboplatin as first-line treatment for advanced, nonsquamous non-small cell lung cancerJ Thorac Oncol201161907191422005471
   PubMed Web of Science ®Google Scholar
• VergnenegreACorreRBerardH0506 GFPC TeamCost-effectiveness of second-line chemotherapy for non-small cell lung cancer: an economic, randomized, prospective, multicenter phase III trial comparing docetaxel and pemetrexed: the GFPC 05-06 studyJ Thorac Oncol2011616116821150465
   PubMed Web of Science ®Google Scholar
• HannaNShepherdFAFossellaFVRandomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapyJ Clin Oncol2004221589159715117980
   PubMed Web of Science ®Google Scholar
• KarampeazisAVamvakasLAgelidouADocetaxel vs. vinorelbine in elderly patients with advanced non – small-cell lung cancer: a hellenic oncology research group randomized phase III studyClin Lung Cancer20111215516021663857
   PubMed Web of Science ®Google Scholar
• KudohSTakedaKNakagawaKPhase III study of docetaxel compared with vinorelbine in elderly patients with advanced non-small-cell lung cancer: results of the West Japan Thoracic Oncology Group Trial (WJTOG 9904)J Clin Oncol2006243657366316877734
   PubMed Web of Science ®Google Scholar
• KrzakowskiMRamlauRJassemJPhase III trial comparing vinflunine with docetaxel in second-line advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapyJ Clin Oncol2010282167217320351334
   PubMed Web of Science ®Google Scholar
• KubotaKWatanabeKKunitohHJapanese Taxotere Lung Cancer Study GroupPhase III randomized trial of docetaxel plus cisplatin versus vindesine plus cisplatin in patients with stage IV non-small-cell lung cancer: the Japanese Taxotere Lung Cancer Study GroupJ Clin Oncol20042225426114722033
   PubMed Web of Science ®Google Scholar
• HongWKThe current status of docetaxel in solid tumors. An M. D. Anderson Cancer Center ReviewOncology (Williston Park)20021691512108903
   PubMed Web of Science ®Google Scholar
• CrownJO’LearyMThe taxanes: an updateLancet20003551176117810791395
   PubMed Web of Science ®Google Scholar
• FultonBSpencerCMDocetaxel. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of metastatic breast cancerDrugs199651107510928736622
   PubMed Web of Science ®Google Scholar
• JinYSunYShiXMeta-analysis to assess the efficacy and toxicity of docetaxel-based doublet compared with docetaxel alone for patients with advanced NSCLC who failed first-line treatmentClin Ther2014361980199025256387
   PubMed Web of Science ®Google Scholar
• MoudiMGoRYienCYNazreMVinca alkaloidsInt J Prev Med201341231123524404355
   PubMedGoogle Scholar
• BennounaJBretonJLTouraniJMVinflunine – an active chemotherapy for treatment of advanced non-small-cell lung cancer previously treated with a platinum-based regimen: results of a phase II studyBr J Cancer2006941383138816641911
   PubMed Web of Science ®Google Scholar
• Al-SalehKQuintonCEllisPMRole of pemetrexed in advanced non-small-cell lung cancer: meta-analysis of randomized controlled trials, with histology subgroup analysisCurr Oncol201219e9e1522328848
   PubMed Web of Science ®Google Scholar
• SmitEFMattsonKvon PawelJManegoldCClarkeSPostmusPEALIMTA (pemetrexed disodium) as second-line treatment of non-small-cell lung cancer: a phase II studyAnn Oncol20031445546012598353
   PubMed Web of Science ®Google Scholar
• LiXWangHLinWXuQEfficacy of combining targeted therapy with pemetrexed or docetaxel as second-line treatment in patients with advanced non-small-cell lung cancer: a meta-analysis of 14 randomized controlled trialsCurr Med Res Opin2014302295230424701984
   PubMed Web of Science ®Google Scholar
• LiRSunLWangJQianJWangZJiaoXPemetrexed versus docetaxel in second line non-small-cell lung cancer: results and subsets analyses of a multi-center, randomized, exploratory trial in Chinese patientsPulm Pharmacol Ther20122536437022766314
   PubMed Web of Science ®Google Scholar
• DouillardJYLaporteSFossellaFComparison of docetaxel- and vinca alkaloid-based chemotherapy in the first-line treatment of advanced non-small cell lung cancer: a meta-analysis of seven randomized clinical trialsJ Thorac Oncol2007293994617909357
   PubMed Web of Science ®Google Scholar
• KlionskyDJAbdallaFCAbeliovichHGuidelines for the use and interpretation of assays for monitoring autophagyAutophagy2012844554422966490
   PubMed Web of Science ®Google Scholar
• SunCTXuXShengWWangXWWenSLHanJQA meta-analysis of pemetrexed-based doublet compared with pemetrexed alone for the second-line treatment of advanced non-small-cell lung cancerBratisl Lek Listy201411523323724797599
   PubMed Web of Science ®Google Scholar